What data does the API provide for BIIB?

Company profile, financial statements, computed ratios, price data, filings and news for BIIB, via REST endpoints under /api/v1/companies/BIIB. Every financial field carries a source tag for provenance.

How complete is BIIB's financial data?

The anchor reporting period (FY2025) has 88.2% of the 17 core statement fields populated. Primary source: sec_edgar.

What reporting periods are covered for BIIB?

5 fiscal-year periods are stored (FY2021–FY2025), with per-period field counts and source tags available via /api/v1/companies/BIIB/financials.

Where does BIIB's data come from?

Primary source for the latest statements: sec_edgar. The API records a source tag on every field and exposes them via /api/v1/companies/BIIB/financials, so each value is traceable.

BIIB — Biogen API Data: Financials, Filings, Coverage

Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Employees: 7,500 · Website: https://www.biogen.com · Profile fields populated: 75%

Data completeness by statement

Share of stored fields populated in the anchor reporting period (FY2025), primary source sec_edgar. Full per-field breakdown: GET /api/v1/companies/BIIB/financials.

Income statement8/10 fields (80.0%)

Balance sheet14/14 fields (100.0%)

Cash flow5/6 fields (83.3%)

Per-share3/4 fields (75.0%)

Financial statement coverage (USD)

Stored values for the most recent fiscal-year periods, with per-period field counts and the primary source each period came from. Values are shown at reported scale without interpretation.

Period	Period end	Fields populated	Source
FY2025	2025-12-31	30	sec_edgar
FY2024	2024-12-31	30	sec_edgar
FY2023	2023-12-31	30	sec_edgar
FY2022	2022-12-31	30	sec_edgar
FY2021	2021-12-31	31	sec_edgar

Get BIIB data via the API

Every number on this page is one API call away. Free API keys — no card required.

Company profile

Name, sector, industry, HQ, employees, market cap, source-tagged.

GET /api/v1/companies/BIIB

Financial statements

Multi-year statements with per-field source tags and completeness.

GET /api/v1/companies/BIIB/financials

Computed ratios

P/E, P/B, ROE, ROA, margins, EPS, debt/equity — formulas documented.

GET /api/v1/companies/BIIB/metrics/summary

Filings archive

Report PDFs with LLM-ready markdown conversions where available.

GET /api/v1/companies/BIIB/filings

News & announcements

Dated press releases and announcements with source links.

GET /api/v1/companies/BIIB/news

Quick start

Create a free key, then:

curl -H "X-API-Key: KEY" https://stockmarketapi.ai/api/v1/companies/BIIB

Query BIIB programmatically

Free tier — instant API key. Built for AI agents.

API Docs AI Agent Setup

Other NASDAQ · Health Care companies covered

Vertex Pharmaceuticals

MRNA

Moderna

REGN

Regeneron Pharmaceuticals

Frequently Asked Questions

What data does the API provide for BIIB?: Company profile, financial statements, computed ratios, price data, filings and news for BIIB, via REST endpoints under /api/v1/companies/BIIB. Every financial field carries a source tag for provenance.
How complete is BIIB's financial data?: The anchor reporting period (FY2025) has 88.2% of the 17 core statement fields populated. Primary source: sec_edgar.
What reporting periods are covered for BIIB?: 5 fiscal-year periods are stored (FY2021–FY2025), with per-period field counts and source tags available via /api/v1/companies/BIIB/financials.
Where does BIIB's data come from?: Primary source for the latest statements: sec_edgar. The API records a source tag on every field and exposes them via /api/v1/companies/BIIB/financials, so each value is traceable.